Business
ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials
Scaled-up, proprietary GMP manufacturing process to be utilized in 2 clinical trials:2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma
About this update from Immix Biopharma, Inc.
[{"type":"text","content":"Scaled-up, proprietary GMP manufacturing process to be utilized in 2 clinical trials:2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”)2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tumors A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/49d68ad5-624b-46b9-8f15-cc07b6717d92 LOS ANGELES, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced that it has completed Good Manufacturing Practice (“GMP”) manufacturing of a scaled-up batch of IMX-110 for clinical trials. IMX-110 was produced using our proprietary, scaled-up manufacturing process that will provide drug supply for 2 ImmixBio clinical trials planned to start in 2022: first, planned monotherapy IMX-110 clinical trial in soft tissue sarcoma (“STS”); second, planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab clinical trial in advanced solid tumors. “Completing the first batch of GMP IMX-110 using our proprietary, scaled-up GMP manufacturing process just 7 months after our manufacturing kick-off is a testament to the efficiency and dedication of our stellar team,” said Ilya Rachman, MD PhD, CEO of ImmixBio. “Building on promising clinical and animal data for IMX-110 as a monotherapy and in combination with PD-1, we are excited to kick off 2 clinical trials soon in 2022 – IMX-110 monotherapy, and IMX-110 combined with BeiGene anti-PD-1 tislelizumab.” About IMX-110 The U.S. Food and Drug Administration (“FDA”) has approved orphan drug designation (“ODD”) for IMX-110 for the treatment of soft tissue sarcoma. Additionally, the FDA has approved rare pediatric disease designation (“RPDD”) for IMX-110 for the treatment of a life-threatening pediatric cancer in children, rhabdomyosarcoma. RPDD qualifies ImmixBio to receive fast track review and a priority review voucher (PRV) at the time of marketing approval of IMX-110. IMX-110 is currently being evaluated in a phase 1b/2a clinical trial in patients with advanced solid tumors. Learn more at www.immixbio.com/iMX-110. About Immix Biopharma, Inc. Immix Biopharma, Inc. (ImmixBio™) (Nasdaq: IMMX)...